-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 26, Jingxin Pharmaceutical issued an announcement stating that the company and South Korea’s Bio-Pharm Solutions Co.
According to the agreement, the company has obtained two clinical indications (infant spasm is in phase II clinical trials in the United States, and focal epilepsy has completed phase I clinical trials in the United States) in mainland China (including Hong Kong, Macau) exclusive clinical research and development, production and commercialization rights
This transaction does not constitute a connected transaction, nor does it constitute a major asset reorganization as required by the Measures for the Administration of Major Asset Reorganizations of Listed Companies